Abiopharma

Trustee’s report to the holders of BONDS 1 for the period from June 19, 2025 until the date of this report, by Hermetic Trust (1975) Ltd.

Quantum Announces Preliminary Fiscal Fourth Quarter 2026 Financial Results

Morgan Stanley Expansion Capital Leads $33 Million Growth Financing For Subtle Medical

Stratasys Celebrates Grand Opening of Americas Headquarters in Minnesota

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

U.S. District Court Issues Decision Regarding CINVANTI® Patents

Gaxos Secures Additional Funding from Amazon AWS to Accelerate AI Sales Platform Development

Zebra Technologies Empowers Frontline Workers with New DNA Software Platforms and AI-Powered Solutions

Stefan Knighton Joins Karman Space & Defense as Company’s First Chief Information and Artificial Intelligence Officer

Camizestrant combination delayed time to first progression in patients with advanced HR-positive breast cancer with an ESR1 tumour mutation